ClinicalTrials.gg
Active, not recruitingNCT06783881Updated Mar 16, 2026

Single-ascending Dose Study of Kylo-12 in Healthy Subjects

A Phase 1 interventional study of Kylo-12 and Placebo in Hypertriglyceridemia, sponsored by Kylonova (Xiamen) Biopharma co., LTD.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Kylonova (Xiamen) Biopharma co., LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Hypertriglyceridemia with a site in China — 14 open to participants now, 19 under way, 5 of them phase 3. Hypertriglyceridemia · China.

Planned enrollment
19th of 25
50 · median 119
Started
2025
with 6 others
Phase 1
5 of 26
3 open now
Primary completion
2025-12
later than 1 of 18 live
Registered
9th of 26
by date

Among the 26 studies in Hypertriglyceridemia with a site in China, this one is the 19th largest by planned enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 1 of the 18 other live ones, and was the 9th registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

14 of the 26 studies in Hypertriglyceridemia with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hypertriglyceridemia with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in healthy volunteers. Kylo-12 will be evaluated in approximately 50 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.

03

Conditions studied

  • Hypertriglyceridemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 to 55 years old, inclusive;
  • (BMI) between 19 kg/m2 and 30 kg/m2, inclusive;
  • Protocol-defined elevated serum TG level;
  • Female subjects must not be able to get pregnant and male subjects must agree to adhere to restrictions;
  • Willing to comply with protocol required visits and assessments, and provide written .

Exclusion criteria

Exclusion Criteria:

  • History or evidence of a disorder, condition or disease;
  • Received an drug, vaccine or device within 3 months before dosing;
  • History of evidence of malignant tumor or Gilbert syndrome;
  • Positive screen of surface antigen, virus, or syphilis infection;
  • History of alcohol abuse within 12 months before dosing;
  • History of drug abuse within 3 months before screening;
  • History of blood donations or blood loss of 400 ml and more within 3 months before dosing;
  • History of stroke or myocardial infarction within 6 months before sceening;
  • Pregnant or breast-feeding women;
  • Other exclusion criteria applied per protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Kylo-12

    Single ascending doses of Kylo-12 administered subcutaneously (SC).

    Drug: Kylo-12

  • Placebo comparator
    Placebo

    Administered SC.

    Drug: Placebo

Interventions

  • DrugKylo-12

    Administered SC.

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: up to Week 24

Secondary outcomes

  1. Incidence of adverse events

    Time frame: up to week 48

  2. Pharmacokinetics (PK) parameter of maximum observed concentration (Cmax)

    Time frame: up to Week 48

  3. PK parameter of time of maximum observed concentration (Tmax)

    Time frame: up to Week 48

  4. PK parameter of area under the concentration time curve (AUC)

    Time frame: up to Week 48

  5. Change in serum ApoC3 and TG over time

    Time frame: up to Week 48

  6. Percent change in serum ApoC3 and TG over time

    Time frame: up to Week 48

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Dec 2025, 9 months.

Of 15 phase 1 interventional studies under Hypertriglyceridemia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 28. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
Mar 12, 2025
Primary completionActual
Dec 19, 2025
CompletionEst.
Aug 30, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06783881
Lead sponsor
Kylonova (Xiamen) Biopharma co., LTD.
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Mar 12, 2025
Primary completion
Dec 19, 2025
Completion
Aug 30, 2026 (estimated)
Last update
Mar 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion